Lung Cancer
Conditions
Brief summary
The purpose of this study is to studying neoadjuvant gefitinib followed by surgery, followed by adjuvant gefitinib to see how well it works in treating patients with unresectable stage III NSCLC harboring EGFR mutations.
Detailed description
Concurrent chemoradiotherapy is the recommended therapeutic approach for patients with unresectable stage III non-small cell lung cancer (NSCLC), although surgery offers the chance of cure. With combined-modality therapy with radiation therapy and chemotherapy, the prognosis of stage III NSCLC remains poor. Gefitinib has shown great efficacy in NSCLC patients with EGFR mutations. This study is to studying neoadjuvant gefitinib followed by surgery, followed by adjuvant gefitinib to see how well it works in treating patients with unresectable EGFR mutant stage III NSCLC.
Interventions
PROCEDUREGefitinib-surgery-gefitinib
neoadjuvant gefitinib followed by surgery, followed by adjuvant gefitinib
Sponsors
Sun Yat-sen University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Target population is unresectable stage III (III A-bulky N2, III B) NSCLC with EGFR activating mutation in exon 19 or 21 * Written informed consent provided * Aged 18-75 years * Able to comply with the required protocol and follow-up procedures * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Had a life expectancy of 12 weeks or more * Adequate hematological function, liver function and renal function * Female participants should not be pregnant or breast-feeding
Exclusion criteria
* Known severe hypersensitivity to gefitinib or any of the excipients of this product * Inability to comply with protocol or study procedures * Had had previous chemotherapy, radiotherapy, or agents directed at the HER axis (e.g. erlotinib, gefitinib, cetuximab, trastuzumab) * Had a history another malignancy in the last 5 years with the exception of cured basal cell carcinoma of the skin, cured in situ carcinoma of the uterine cervix and cured epithelial carcinoma of the bladder * Interstitial pneumonia * Eye inflammation not fully controlled or conditions predisposing the subject to this * Any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease) * Known human immunodeficiency virus (HIV) infection * Pregnancy or breast-feeding women * History of neurologic or psychiatric disorders * Ingredients mixed with small cell lung cancer patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Resectability rate | 3 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with perioperative complications | 1 year | — |
| Event-free survival | 2 years after the last patient is randomized | Event-free survival was assessed from randomization to disease recurrence/progression or death from any cause. |
| Overall survival | 2 years after the last patient is randomized | Overall survival was assessed from randomization to death from any cause. |
Countries
China
Outcome results
None listed